Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
---|---|---|---|---|---|---|
Roche | Satralizumab | Enspryng |  | 2021-06-24 | $289.79 M | Q4/22-Q3/23 |
Horizon Therapeutics Public | Inebilizumab | Uplizna |  | 2020-06-11 |  |  |
Genentech | Satralizumab | Enspryng |  | 2020-08-14 |  |  |
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
---|---|---|---|---|---|